<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01270659</url>
  </required_header>
  <id_info>
    <org_study_id>1774</org_study_id>
    <nct_id>NCT01270659</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury</brief_title>
  <acronym>FAIRTOP II</acronym>
  <official_title>Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate fentanyl buccal tablet (FBT) for analgesia
      in comparison to standard analgesia, to determine if the FBT allows for faster achievement of
      &quot;significant analgesia&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects/patients will be asked if they would desire a low dose or high dose pain
      medication regimen. The low dose (low-FBT) group will receive FBT at a dose of 100 mcg, as
      well as an oral (pill) placebo preparation. The low dose (low-control) group will receive an
      &quot;inactive comparator&quot; (lansoprazole rapidly-dissolving buccal 15mg, &quot; FBT placebo&quot;) and a
      dose of 5/325 Percocet tablet (oxycodone/acetaminophen 5/325). The high dose (high-FBT) group
      will receive 200 mcg FBT plus 2 placebo tablets. The high dose (high-control) group will
      receive the &quot;FBT placebo&quot; and a dose of 2, 5/325 Percocet tablets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Median time (in minutes) to 2 units decrease in pain level after drug administration. Patients were asked to rate their pain at every 5 minutes intervals from 0 to 60 minutes post drug administration. The 10-point verbally administered numeric pain rating scale (NPRS) was used to have patients rate their level of pain on a scale of 0 (no pain) to 10 (worst pain ever).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea Level</measure>
    <time_frame>every 5 minutes for the first 60 minutes</time_frame>
    <description>Subjects' nausea level was recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea. Treatment induced nausea and severity of nausea level was assessed.
Nausea was assessed by a 10-point verbally administered scale. Patients rated their degree of nausea on a scale of 0 (no nausea) to 10 (worst nausea).
At the beginning of the study, literature review found relatively little evidence guiding objective means to rate nausea, but there was some precedent for this approach (Warden C. Prehospital use of ondansetron reduces nausea and episodes of vomiting in adults and children over 12 years old [abstract]. Prehosp Emerg Care. 2007;11:132).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Any Adverse Events</measure>
    <time_frame>Full 2 hours of the study period</time_frame>
    <description>Occurrence of any adverse event.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Low-FBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive FBT and placebo at a low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-FBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive the high dose regimen of FBT and a high dose placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl buccal tablet 100 mcg once</description>
    <arm_group_label>Low-FBT</arm_group_label>
    <other_name>Fentora 100 mcg buccal tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl buccal tablet 200 mcg once</description>
    <arm_group_label>High-FBT</arm_group_label>
    <other_name>Fentora buccal tablet 200 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone/acetaminophen</intervention_name>
    <description>Oxycodone/acetaminophen 5/325 mg once</description>
    <arm_group_label>Low control</arm_group_label>
    <other_name>Percocet 5/325</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxycodone/acetaminophen</intervention_name>
    <description>Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
    <arm_group_label>High control</arm_group_label>
    <other_name>Percocet 5/325</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pain sufficient to warrant medication stronger than acetaminophen (Tylenol) or aspirin

          -  only if Emergency Department provider approves

          -  a negative pregnancy test is required for participation for women of childbearing age

        Exclusion Criteria:

          -  If treating provider determines intravenous analgesia is required

          -  allergy to acetaminophen or any opiate/opioid, or lansoprazole patients currently
             taking phenothiazines, CNS depressants (including alcohol), or if they have taken an
             monoamine oxidase inhibitor (MAOI) or selective serotonin reuptake inhibitor (SSRI) in
             the past two weeks

          -  if patient has already been administered an opioid analgesic for their current injury

          -  patients on chronic opioids therapy or a history of opioid abuse

          -  breastfeeding mothers

          -  patients who plan to drive home after their emergency department visit

          -  history of phenylketonuria (due to phenylalanine in the formulation of the
             lansoprazole solutab)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen H Thomas, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annette O Arthur, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillcrest Medical Center Emergency Department</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2017</results_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fentanyl buccal tablet</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low-FBT</title>
          <description>Subject will receive FBT and placebo at a low dose
Fentanyl: Fentanyl buccal tablet 100 mcg once</description>
        </group>
        <group group_id="P2">
          <title>High-FBT</title>
          <description>Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl: Fentanyl buccal tablet 200 mcg once</description>
        </group>
        <group group_id="P3">
          <title>Low Control</title>
          <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;
Oxycodone/acetaminophen: Oxycodone/acetaminophen 5/325 mg once</description>
        </group>
        <group group_id="P4">
          <title>High Control</title>
          <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;
oxycodone/acetaminophen: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-FBT</title>
          <description>Subject will receive FBT and placebo at a low dose
Fentanyl: Fentanyl buccal tablet 100 mcg once</description>
        </group>
        <group group_id="B2">
          <title>High-FBT</title>
          <description>Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl: Fentanyl buccal tablet 200 mcg once</description>
        </group>
        <group group_id="B3">
          <title>Low Control</title>
          <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;
Oxycodone/acetaminophen: Oxycodone/acetaminophen 5/325 mg once</description>
        </group>
        <group group_id="B4">
          <title>High Control</title>
          <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;
oxycodone/acetaminophen: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="10.01"/>
                    <measurement group_id="B2" value="38.4" spread="13.7"/>
                    <measurement group_id="B3" value="34.0" spread="13.1"/>
                    <measurement group_id="B4" value="35.4" spread="11.9"/>
                    <measurement group_id="B5" value="35.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level)</title>
        <description>Median time (in minutes) to 2 units decrease in pain level after drug administration. Patients were asked to rate their pain at every 5 minutes intervals from 0 to 60 minutes post drug administration. The 10-point verbally administered numeric pain rating scale (NPRS) was used to have patients rate their level of pain on a scale of 0 (no pain) to 10 (worst pain ever).</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-FBT</title>
            <description>Subject will receive FBT and placebo at a low dose
Fentanyl: Fentanyl buccal tablet 100 mcg once</description>
          </group>
          <group group_id="O2">
            <title>High-FBT</title>
            <description>Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl: Fentanyl buccal tablet 200 mcg once</description>
          </group>
          <group group_id="O3">
            <title>Low Control</title>
            <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;
Oxycodone/acetaminophen: Oxycodone/acetaminophen 5/325 mg once</description>
          </group>
          <group group_id="O4">
            <title>High Control</title>
            <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;
oxycodone/acetaminophen: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level)</title>
          <description>Median time (in minutes) to 2 units decrease in pain level after drug administration. Patients were asked to rate their pain at every 5 minutes intervals from 0 to 60 minutes post drug administration. The 10-point verbally administered numeric pain rating scale (NPRS) was used to have patients rate their level of pain on a scale of 0 (no pain) to 10 (worst pain ever).</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.0">Due to small sample size not enough participants achieved response to calculate upper limit.</measurement>
                    <measurement group_id="O2" value="20.0" lower_limit="15.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="5.0">Due to small sample size not enough participants achieved response to calculate upper limit.</measurement>
                    <measurement group_id="O4" value="15.0" lower_limit="10.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea Level</title>
        <description>Subjects' nausea level was recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea. Treatment induced nausea and severity of nausea level was assessed.
Nausea was assessed by a 10-point verbally administered scale. Patients rated their degree of nausea on a scale of 0 (no nausea) to 10 (worst nausea).
At the beginning of the study, literature review found relatively little evidence guiding objective means to rate nausea, but there was some precedent for this approach (Warden C. Prehospital use of ondansetron reduces nausea and episodes of vomiting in adults and children over 12 years old [abstract]. Prehosp Emerg Care. 2007;11:132).</description>
        <time_frame>every 5 minutes for the first 60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-FBT</title>
            <description>Subject will receive FBT and placebo at a low dose
Fentanyl: Fentanyl buccal tablet 100 mcg once</description>
          </group>
          <group group_id="O2">
            <title>High-FBT</title>
            <description>Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl: Fentanyl buccal tablet 200 mcg once</description>
          </group>
          <group group_id="O3">
            <title>Low Control</title>
            <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;
Oxycodone/acetaminophen: Oxycodone/acetaminophen 5/325 mg once</description>
          </group>
          <group group_id="O4">
            <title>High Control</title>
            <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;
oxycodone/acetaminophen: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea Level</title>
          <description>Subjects' nausea level was recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea. Treatment induced nausea and severity of nausea level was assessed.
Nausea was assessed by a 10-point verbally administered scale. Patients rated their degree of nausea on a scale of 0 (no nausea) to 10 (worst nausea).
At the beginning of the study, literature review found relatively little evidence guiding objective means to rate nausea, but there was some precedent for this approach (Warden C. Prehospital use of ondansetron reduces nausea and episodes of vomiting in adults and children over 12 years old [abstract]. Prehosp Emerg Care. 2007;11:132).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Any Adverse Events</title>
        <description>Occurrence of any adverse event.</description>
        <time_frame>Full 2 hours of the study period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low-FBT</title>
            <description>Subject will receive FBT and placebo at a low dose
Fentanyl: Fentanyl buccal tablet 100 mcg once</description>
          </group>
          <group group_id="O2">
            <title>High-FBT</title>
            <description>Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl: Fentanyl buccal tablet 200 mcg once</description>
          </group>
          <group group_id="O3">
            <title>Low Control</title>
            <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;
Oxycodone/acetaminophen: Oxycodone/acetaminophen 5/325 mg once</description>
          </group>
          <group group_id="O4">
            <title>High Control</title>
            <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;
oxycodone/acetaminophen: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Any Adverse Events</title>
          <description>Occurrence of any adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All study patients were monitored during the entire study period i.e., 2 hours after medication administration.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low-FBT</title>
          <description>Subject will receive FBT and placebo at a low dose
Fentanyl: Fentanyl buccal tablet 100 mcg once</description>
        </group>
        <group group_id="E2">
          <title>High-FBT</title>
          <description>Subject will receive the high dose regimen of FBT and a high dose placebo
Fentanyl: Fentanyl buccal tablet 200 mcg once</description>
        </group>
        <group group_id="E3">
          <title>Low Control</title>
          <description>Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl &quot;placebo&quot;
Oxycodone/acetaminophen: Oxycodone/acetaminophen 5/325 mg once</description>
        </group>
        <group group_id="E4">
          <title>High Control</title>
          <description>Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl &quot;placebo&quot;
oxycodone/acetaminophen: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nasir Mushtaw</name_or_title>
      <organization>University of Oklahoma Health Sciences Center Tulsa</organization>
      <phone>918/660-3680</phone>
      <email>Nasir-Mushtaq@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

